Barry Kappel, Sapience Therapeutics CEO
May 31, 2022 10:53 AM EDTUpdated 04:54 PM
Financing
Startups

Pep­tide biotech gets re­newed sup­port from Bris­tol My­ers, oth­ers to bankroll mul­ti­ple on­col­o­gy clin­i­cal pro­grams

Kyle LaHucik

Senior Reporter

The first batch of fi­nanc­ing last­ed about five years, but this time around, Sapi­ence Ther­a­peu­tics thinks its new fund­ing round will have run­way for less …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times